KING OF PRUSSIA, PA, UNITED STATES - Nov 27, 2018 - Greenphire, the global leader in financial technology for clinical trials, announced today that it has been ranked as 391 on Deloitte's 2018 Technology Fast 500™. This is the fifth consecutive year that Greenphire has been recognized with this honor, which ranks the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. Greenphire exhibited a 199 percent growth over a three-year period.

"We are honored to once again be named among the fastest-growing technology companies in North America," said Jim Murphy, CEO of Greenphire. "Our continued year-over-year growth reflects the company's dedication to transforming payment workflows with automation that improves efficiency and quality across multiple clinical research process stakeholders including participants, sites, CROs and sponsors."

Greenphire automates and streamlines site and participant payment processes, supporting monthly site payments globally with eClinicalGPS and instant, secure participant reimbursements and stipends via ClinCard. With more than 600 clients, including 9 of the top 10 pharmaceutical companies, Greenphire has facilitated more than 6.5 million participant reimbursements and more than 1.3 million automated investigator payments.

Greenphire's continued recognition by the Deloitte Technology Fast 500™ is a testament to the company's focus on building and maintaining strong collaborative relationships and consistently delivering the most sophisticated technology in the market, designed to be flexible and scalable to meet the dynamic needs of clinical research.

About Greenphire 
Greenphire is the global leader in clinical trial payment software. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials. Learn more at www.greenphire.com.

Media Contact:
Amy Sitnick
Greenphire
215-609-4315
amy.sitnick@greenphire.com